Abstract
Introduction: Sonidegib is approved in the US to treat locally advanced basal cell carcinoma (laBCC) not amenable to surgery or radiation. The BOLT trial for sonidegib used modified Response Evaluation Criteria in Solid Tumors (mRECIST) for laBCC tumor evaluation, while ERIVANCE trial for vismodegib used RECIST. This preplanned sensitivity analysis in BOLT trial applied RECIST criteria to laBCC tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
